The TRIDENT study is a post-hoc analysis of the phase III POSEIDON trial, which evaluated the addition of tremelimumab to durvalumab and chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). This analysis utilized machine learning models integrating clinical, genomic, and radiomic data to identify patients who would derive greater overall survival (OS) benefit from the addition of tremelimumab. Results showed that the top-ranked 50% of patients with nonsquamous tumors, as identified by the model, achieved a hazard ratio of 0.56 for OS. Factors such as KRAS and STK11 mutations, along with wild-type EGFR, FGFR3, and CDKN2A, were strongly associated with higher OS benefit.
Cervical adenocarcinoma is linked to poorer survival and reduced response to immunotherapy. This study identified STK11 alterations, including mutations and focal deletions, as a distinct feature of HPV-positive cervical adenocarcinomas, affecting 23% of these tumors. These alterations are associated with a younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor therapy. Comprehensive genomic analyses revealed complex structural rearrangements involving chromosome 19p and STK11. These findings define an aggressive molecular subgroup and have implications for molecular classification and future targeted therapeutic strategies.
This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.
Otolaryngologia polska = The Polish otolaryngology ·
This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.